H.U. Group Holdings, Inc.

Equities

4544

JP3822000000

Healthcare Facilities & Services

Market Closed - Japan Exchange Other stock markets 02:00:00 2024-04-26 am EDT			5-day change	1st Jan Change
2,416 ^JPY	+0.86%		+3.85%	-9.29%

Apr. 26	H.U. Group Holdings, Inc. Announces Retirement of Atsuko Murakami as Executive Officer	CI
Apr. 26	H.U. Group Holdings, Inc. Announces Retirement of Atsuko Murakami as Chief Financial Officer	CI

H.U. Group Holdings, Inc. Provides Consolidated Earnings Forecasts for the Fiscal Year Ending March 31, 2024

May 16, 2023 at 02:00 am EDT

H.U. Group Holdings, Inc. provided Consolidated earnings forecasts for the fiscal year ending March 31, 2024. For the period, the company expected net sales of JPY 245,000 million, Operating profit of JPY 14,000 million, Profit attributable to owners of parent of JPY 6,000 million and Basic EPS of JPY 105.43.

Latest news about H.U. Group Holdings, Inc.

H.U. Group Holdings, Inc. Announces Retirement of Atsuko Murakami as Executive Officer	Apr. 26	CI
H.U. Group Holdings, Inc. Announces Retirement of Atsuko Murakami as Chief Financial Officer	Apr. 26	CI
H.U Unit Fujirebio Diagnostics Partners Beckman Coulter in Neurodegenerative Diseases Field	Mar. 13	MT
Fujirebio and Beckman Coulter Expand Partnership to Develop Patient-Friendly, Blood-Based Neurodegenerative Disease Diagnostics	Mar. 12	CI
H.U. Group Holdings Inc. and Fujirebio Announces the Availability of the Lumipulse G pTau 217 Plasma Assay for the Fully Automated LUMIPULSE G Immunoassay Systems	Dec. 22	CI
Japanese Shares Rebound After Inflation Data, BoJ Rate Outlook	Dec. 22	MT
H.U. Group to Issue Stock Options to Directors, Employees	Dec. 21	MT
H.U. Group to Grant Share Options to Staff	Nov. 19	MT
H.U. Group Holdings, Inc. Revises Earnings Guidance for the Fiscal Year Ending March 31, 2024	Nov. 09	CI
H.U. Group Holdings, Inc.(TSE:4544) dropped from FTSE All-World Index	23-09-18	CI
H.U. Group Holdings' Fiscal Full-Year Profit Falls 47%	23-05-17	MT
H.U. Group Holdings, Inc. Announces Dividend for the Year Ended March 31, 2023, Payable on May 30, 2023; Provides Dividend Guidance for the Second Quarter and Full Year Ending March 31, 2024	23-05-16	CI
H.U. Group Holdings, Inc. Provides Consolidated Earnings Forecasts for the Fiscal Year Ending March 31, 2024	23-05-16	CI
H.U. Group Holdings, Inc. Reports Earnings Results for the Full Year Ended March 31, 2023	23-05-12	CI
H.U. Group Holdings, Inc. Announces Launch of the Fully Automated Lumipulse® G NfL CSF and Lumipulse® G NfL Blood tests	23-03-28	CI
H.U. Group Holdings, Inc. Provides Consolidated Earnings Forecasts for the Fiscal Year Ending March 31, 2023	23-02-10	CI
H.U. Group Holdings, Inc. Provides Year End Dividend Forecast for the Fiscal Year Ending March 31, 2023	23-02-10	CI
H.U. Group Holdings, Inc. Provides Dividend Guidance for the Second Quarter-End and for the Full Year of Fiscal Year Ending March 31, 2023	22-08-15	CI
H.U. Group Holdings, Inc. Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2023	22-08-15	CI
Japan Equities End Week Higher; W-Scope Zooms 12% on Securing Approval for Unit's Listing in Korea	22-06-24	MT
H.U. Group Unit to Acquire Biomarker Assays Developer for $42 million	22-06-24	MT
H.U. Group Holdings, Inc. Provides Dividend Guidance for the Fiscal Year Ended March 31, 2022	22-05-20	CI
H.U. Group Unit Designates Managing Director	22-04-25	MT
H.U. Group Holdings, Inc. Announces Board Changes	22-04-22	CI
H.U. Group Holdings, Inc. Announces Launch of Fully Automated Lumipulse G ß-Amyloid 1-42 and ß-Amyloid 1-40 Plasma Assays for Research Use Only	22-03-30	CI

Chart H.U. Group Holdings, Inc.

Duration

Period

More charts

Company Profile

H.U. Group Holdings Inc, formerly Miraca Holdings Inc is a Japan-based holding company engaged in manufacture and sale of clinical test drugs, entrusted clinical examination and sterilization related business. The Company operates in four business segments. The Outsourced Clinical Testing segment accepts special tests from medical institutions. The Clinical Laboratory Medicine segment manufactures and sells clinical laboratory medicines and sells them to medical institutions and contract clinical laboratory companies. The Sterilization segment mainly entrusts the sterilization of medical equipment used for medical treatment in hospitals of large-scale hospitals and the related operations. The New Development & Others segment is involved in the homecare & welfare equipment business, self-medication & health insurance business, food & environment & cosmetics inspection business.

Sector

Healthcare Facilities & Services

Calendar

2024-05-09 - Q4 2023 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for H.U. Group Holdings, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

A-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

UNDERPERFORM

Number of Analysts

Last Close Price

2,416 JPY

Average target price

2,582 JPY

Spread / Average Target

+6.87%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Medical & Diagnostic Laboratories

	1st Jan change	Capi.
H.U. GROUP HOLDINGS, INC.	-9.29%	872M
SONIC HEALTHCARE LIMITED	-17.89%	8.25B
RADNET, INC.	+39.20%	3.58B
GUANGZHOU KINGMED DIAGNOSTICS GROUP CO., LTD.	-39.11%	2.46B
SYNLAB AG	-8.06%	2.46B
DR. LAL PATHLABS LIMITED	-7.35%	2.38B
NEOGENOMICS, INC.	-12.61%	1.81B
FLEURY S.A.	-19.01%	1.55B
DIAN DIAGNOSTICS GROUP CO.,LTD.	-40.66%	1.21B
METROPOLIS HEALTHCARE LIMITED	+7.56%	1.11B

Medical & Diagnostic Laboratories